Itolizumab for the treatment of lupus nephritis

Itolizumab for the treatment of lupus nephritis The EQUALISE Study is a clinical trial testing an investigational medicine called itolizumab in patients with lupus nephritis.

The EQUALISE Study is a Phase 1b clinical study testing itolizumab (pronounced eet o LIZ u mab), a potential new treatment for lupus nephritis. This clinical study will determine the amount of itolizumab in a patient’s blood or urine when it is administered at varying doses and will tell researchers more about the ideal dose, safety and effectiveness of itolizuma

b in people with lupus nephritis.In this study blood and urine will be tested for markers of lupus nephritis (called biomarkers). This may help physicians individualize treatment for each patient. To test how the biomarker correlates to severity of lupus nephritis, the study will compare levels in individuals with lupus with or without lupus nephritis. To learn more please visit: https://www.clinicaltrials.gov/ct2/show/NCT04128579

Address

San Diego, CA

Alerts

Be the first to know and let us send you an email when Itolizumab for the treatment of lupus nephritis posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Itolizumab for the treatment of lupus nephritis:

Share